Dagenais François, Shetty Rahul, Normand Jean-Pierre, Turcotte Roc, Mathieu Patrick, Voisine Pierre
Department of Cardiac Surgery, Laval Hospital, Québec City, Québec, Canada.
Ann Thorac Surg. 2006 Aug;82(2):567-72. doi: 10.1016/j.athoracsur.2006.03.019.
Thoracic stent-grafts (TSG) show excellent early and mid-term results for localized diseases of the descending aorta. Extending TSG applications for arch pathologies or to other yet unproven indications remains to be established. We herein report our experience in 18 patients with extended applications of TSG.
Ten patients with inadequate proximal aortic neck length required coverage of at least one arch vessel with or without extra-anatomic bypass. One patient required an extra-anatomic visceral bypass to extend the distal aortic neck, 6 patients were treated with TSG for yet unproven indications, and 1 patient required an unusual vascular access.
A mean of 2.4 +/- 1.0 stents per patient were inserted. Primary or secondary success rate was 100%. Hospital mortality occurred in one patient (5.5%). Mean follow-up was 24.1 +/- 13.7 months. Four endoleaks were diagnosed: two of type 1, one of type 2, and one that remains undetermined. Two patients died during follow-up; both deaths were linked to the presence of a type 1 endoleak. Actuarial survival at 3 years was 79.0%. Freedom from endoleak and stent-graft-related death at 3 years were, respectively, 71.0% and 83.7%. No stent-graft migration was observed.
Early and mid-term results of extended applications of TSG are acceptable in well-selected high-risk patients. Endoleak at follow-up remains a concern and may impede long-term outcome of TSG in complex procedures.
对于降主动脉局限性疾病,胸主动脉覆膜支架(TSG)显示出优异的早期和中期效果。将TSG应用扩展至主动脉弓病变或其他未经证实的适应症仍有待确定。我们在此报告18例TSG扩展应用患者的经验。
10例近端主动脉颈部长度不足的患者需要覆盖至少一根主动脉弓血管,伴或不伴有解剖外旁路。1例患者需要解剖外内脏旁路以延长远端主动脉颈部,6例患者接受TSG治疗用于未经证实的适应症,1例患者需要特殊的血管通路。
每位患者平均植入2.4±1.0枚支架。一期或二期成功率为100%。1例患者(5.5%)发生医院死亡。平均随访时间为24.1±13.7个月。诊断出4例假性动脉瘤:2例为1型,1例为2型,1例类型未确定。2例患者在随访期间死亡;均与1型假性动脉瘤的存在有关。3年精算生存率为79.0%。3年无假性动脉瘤和支架移植物相关死亡的发生率分别为71.0%和83.7%。未观察到支架移植物移位。
在精心挑选的高危患者中,TSG扩展应用的早期和中期结果是可以接受的。随访中的假性动脉瘤仍然是一个问题,可能会阻碍复杂手术中TSG的长期效果。